

Welcome!

Franklin King IV, MD Director, Training and Education, Center for Neuroscience of Psychedelics Massachusetts General Hospital



Nuts and bolts

- CME is claimed via your attendance
- Psychologists and SW credit: sign in each day
- Write your name in your book
- Please silence your phones (and alarms)
- Questions for Q&A via link on the slides
- Ask the Psych Academy for lunch options
- Evaluations!



A Brief History of Psychedelics in 20 minutes

Franklin King IV, MD Director, Training and Education, Center for Neuroscience of Psychedelics Massachusetts General Hospital

Disclosures



If you have disclosures, state:

My spouse/partner and I have the following relevant financial relationship with a commercial interest to disclose:

Compass, Cybin – personal stock

Apex Labs – SAB

Tryp Therapeutics – research support

All relations approved by MGH Office of Interaction with Industry



Psychedelics are not new

- Psychedelics are not "novel agents"
- Used across cultures and continents for thousands of years
- Generally used as medicines within a sacred context combining elements of therapy, medicine, and religion
- Broader context of:
 - Psychoactive plants as medicines
 - Elevating non-ordinary states of consciousness as integral aspects to the human experience

Mescaline



- Peyote buttons found in Rio Grande valley, 5700 years ago
- San Pedro cactus in Peru from 3300 years ago






WWW.MGHCME.ORG

El Seedi, J Ethnopharmacol, 2005; Davis *Botanical Museum Leaflets*, 1983

DMT

- Many diverse plants contain DMT
- Ayahuasca (at least 1,000 years ago in Bolivia), Banisteriopsis and Psychotria
- Jurema (northeastern Brazil) -Mimosa
- Tepezcohuite (Mexico) Mimosa
- Cohoba or yopo (Caribbean) -Anadananthera







PSYCHIATRY ACADEMY






Psilocybin

- Extensively used and deeply embedded within Mesoamerican cultures
- Various names, teonanacatl (flesh of the gods), temicxoch (dream flowers)
- Aztecs also consumed morning glory seeds (ololiuqui)
- Brutally suppressed by invading Europeans









Ibogaine


- Shrub native to central and western Africa
- Used likely for millennia
- Highly potent
- Primarily used in large doses in coming of age ceremonies





Psychedelics in western medicine

- Hashish, chloroform, ether (1890s)
- Narcoanalysis (barbiturates, 1920s)
- Confessions in Mescaline Inebriation (1931)
- First clinical study with LSD (1947)
- First use of LSD in therapy (1950)





Psycholytic therapy

- Arose in context of psychoanalysis-dominated era
- Goal to use LSD as an adjunct to therapy, rather being a cure itself
- Amplication of psychodynamic processes and reduction of ego defenses
- Many, frequent, moderate dose LSD sessions embedded within extensive, traditional psychotherapy paradigm
- Predominant model in Europe



Psychedelic therapy

- Inadvertent discoveries that LSD led to significant patient improvement in cancer and alcoholism by inducing mystical and/or religious experiences
- Concurrent refocus within psychology on transcendent states (Maslow, head of APA)
- Growing awareness of Indigenous practices using psychedelics in ritual context



Psychedelic therapy

- One of the predominant forms in North America by latter 1960s
- Explicit purpose to induce mystical or transcendent experience
- Single, high dose session
- Manipulation of expectation and environment to prime this occurrence

Psychedelic therapy 1950s-1970s



- Thousands of participants enrolled in clinical studies, mostly utilizing LSD
- Promising results, particularly in alcohol use disorder and end of life-related depression and anxiety
- However, lower quality research, heterogeneity of studies
- Ultimately a casualty of moral panic over LSD in the USA and Europe



The return of psychedelics

- 1994: DMT study by Rick Strassman
- 2006: "psilocybin can occasion mystical type experiences" (Griffiths, Johns Hopkins)
- 2010s-present: Research grows
- 2019-present: starting with Imperial College (UK) and Johns Hopkins (USA), psychedelic research centers open
- 2021: first Phase III study results reported (MDMA-assisted therapy for PTSD); MGH opens Center for Neuroscience of Psychedelics
- 2024: FDA rejects New Drug Application for MDMA



The Pharmacology of Psychedelics

What are psychedelics?



- Psychedelic, 1956 = "mind-manifesting"
- Change in consciousness, experience often described as profound, transformative, with spiritual or mystical importance, and/or personal meaning
- "Ego dissolution" decreased boundary between self and world, increased connectedness
- Increased sensory experiences: synesthesia, visual imagery and/or hallucinations

How do psychedelics differ?




- Time: LSD and mescaline (8-12 hours), psilocybin and ayahuasca (4-6 hours), DMT and 5-MeO DMT (10-20 minutes)
- Quality:
 - Measures: ASC, MEQ, HRS
 - Visual aspects
 - Ego dissolution/consciousness change
 - Prosociality (MDMA, MDA "empathogens")
- Oral bioavailability: DMT 100% metabolized by gut monoamine oxidase, most others with good oral bioavailability


Classes of Psychedelics




Tryptamines




Benzofurans



Phenethylamines



Cathinones




Tryptamines



PSYCHIATRY ACADEMY

- Most studied class in modern era
- All share structural backbone with serotonin (5hydroxytryptamine)
- Psilocybin (4phosphoryloxy-DMT)
- DMT, 5-MeO-DMT
- LSD








Tryptamines


- Most studied class in modern era
- All share structural backbone with serotonin (5hydroxytryptamine)
- Psilocybin (4phosphoryloxy-DMT)
- DMT, 5-MeO-DMT
- LSD




Phenethylamines

- Substituted phenethylamines include a wide array of drug classes
- Psychedelics include mescaline, MDMA
- Other than MDMA, less well-researched

CNS stimulants, decongestants, antidepressants, anti-Parkinson agents, vasopressors, bronchodilators, and neurotransmitters epinephrine, norepinephrine and dopamine



NH₂



MDMA

WWW.MGHCME.ORG



PSYCHIATRY ACADEMY

Phenethylamines




- "2C" compounds, eg, 2C-B (psychedelic + empathogenic)
- Also include psychedelic agents with higher risk for adverse effects
 - DOM: "STP", extremely potent, long lasting, mistakenly taken as LSD in late 1960s
 - NBOMe's: group of compounds highly potent, sometimes misrepresented as LSD -> overdose
 - Toxicity: tachycardia, fever, hypertension, seizures, hyperthermia

MASSACHUSETTS GENERAL HOSPITAL PSYCHIATRY ACADEMY

Pharmacology

- Primary effect via agonist or partial agonist activity at 5HT-2A receptor
- Blocked by ketanserin and other 5HT-2A antagonists
- Prevention of psychedelic effect shown for psilocybin, LSD



Vollenweider et al, Neuroreport, 1998; Preller et al, Curr Biol, 2017; Preller et al, Elife, 2018



The 5HT-2A receptor

- Excitatory (G-protein coupled receptor, causes neuron to depolarize, release cortical glutamate)
- Expressed throughout the brain, but more densely expressed in certain areas
- Activation associated with neuroplasticity (increase in dendritic spines, synaptic proteins etc)

Safety & physiologic effects




- Subjective physical effects:
 - Headache, nausea, fatigue most common (<50%)
- Sympathetic changes:
 - 个BP, 个HR (mild), 个temperature (mild)
 - Mydriasis, increased reflexes
- Well tolerated in medically ill subjects (advanced cancer, geriatric patients)
- Toxicity: no LD50 established for humans, likely in grams or kilograms
- No evidence for mutagenic effects or neurotoxicity, including high dose exposures

Passie CNS Neuroscience and Therapeutics 2008


Autonomic effects






Psilocybin 🖻

Bogenschutz *Psychopharmacology* 2015, Holze *Neuropsychopharmacology* 2021 LSD



Autonomic effects





Holze *Neuropsychopharmacology* 2019



Tachyphylaxis

- Tachyphylaxis occurs within 3-5 days of daily administration
- Cross-tolerance between different agents
- Correlates with downregulation of 5HT-2A receptors in animal models
- Biological dependence on psychedelics is not possible



Psychedelics and psychiatric medications

- SSRIs tapered off for most psychedelic studies
- Long been thought to blunt the effects of psychedelics
- Recent (but small) studies suggest SSRIs may neither block subjective nor therapeutic effects
- More research needed on this question due to impact on accessibility of psychedelic treatments



Psychedelics and psychiatric medications Psychiatry ACADEMY

- MDMA is fully blocked by SSRIs and SNRIs
- Ayahuasca: contains MAOI 💀
- **Ibogaine: QT prolongation <->** methadone et al.
- Lithium: increased risk of seizure?
- Second generation antipsychotics fully antagonize psychedelic, partial blocking of effect with haloperidol

Liechti et al, Neuropsychopharmacology 2000; Nayak et al, *Pharmacopsychiatry* 2021; Schmid et al *J Pharmacol Exp Ther* 2015; Vollenweider et al *Neuroreport* 2008

Thank you

fking@mgh.harvard.edu



MGH Center for the Neuroscience of Psychedelics



Leadership

- Jerrold Rosenbaum, MD CNP Director MGH Department of Psychiatry
- Sharmin Ghaznavi, MD, PhD

CNP Associate Director and Director of Cognitive Neuroscience MGH Department of Psychiatry

• Bruce Rosen, MD, PhD

Scientific Director, Neuroimaging Athinoula A. Martinos Center for Biomedical Imaging

• Jacob Hooker, PhD

Director, Translational Biomarkers Athinoula A. Martinos Center for Biomedical Imaging

Stephen Haggarty, PhD

CNP Scientific Director, Chemical Neurobiology MGH Department of Neurology

• Franklin King, MD

CNP Director of Education and Therapist Training MGH Department of Psychiatry

• Jeremy Ruskin, MD Founder, MGH Cardiac Arrhythmia Service